Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CasNano is an ultracompact engineered CRISPR-associated (Cas) protein developed by Epitor Therapeutics. Comprising fewer than 400 amino acids, it is designed as a highly compact genome-editing tool that can be efficiently packaged into adeno-associated virus (AAV) vectors, overcoming the size limitations of traditional Cas proteins such as spCas9. CasNano enables targeted gene editing and epigenetic modulation—including demethylation, methylation, and gene activation or repression—by fusing with various protein effectors. It supports multiplexed editing and demonstrates over a 20-fold improvement in targeting efficiency due to directed evolution and re-engineering of its guide RNA components. Its small size allows co-packaging with large effectors like TET demethylases for precise epigenetic editing within a single AAV vector[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CasNano.